Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6(1): 85-95.
Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004; 27(2): 317-21.
Lam SP, Fong SYY, Ho CKW, Yu MWM, Wing YK. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry 2008; 69(9): 1374-82.
Lee K, Baron K, Soca R, Attarian H. The prevalence and characteristics of REM sleep without atonia (RSWA) in patients taking antidepressants. J Clin Sleep Med 2016; 12(3): 351-5.
Zhang B, Hao Y, Jia F, et al. Sertraline and rapid eye movement sleep without atonia: an 8-week, open-label study of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2013; 47: 85-92.
Tan L, Zhou J, Yang L, et al. Duloxetine-induced rapid eye movement sleep behavior disorder: a case report. BMC Psychiatry 2017; 17(1): 372.
Mahowald MW, Kim SW, O’Connor KA, Hurwitz TD. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated. Sleep 1992; 15(3): 226-35.
Parish JM. Violent dreaming and antidepressant drugs: or how paroxetine made me dream that I was fighting Saddam Hussein. J Clin Sleep Med 2007; 3(5): 529-31.
Williamsa R, Sandigob G. Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures. Trauma Case Rep 2017; 11: 18-9.
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72(15): 1296-300.
Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep 2013; 36(11): 1579-85.
Dores GM1. Bryant-Genevier M1, Perez-Vilar S1. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s adverse event reporting system, 2010-2017. JAMA Netw Open 2019; 2(8)e199249
Raschi E1. Girardi A2, Poluzzi E2, Forcesi E2, Menniti-Ippolito F3, Mazzanti G4, De Ponti F2. Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems. Drug Saf 2018; 41(8): 745-52.
Tibau A1. Ocana A2, Anguera G1, Seruga B3, Templeton AJ4, Barnadas A1, Amir E5. Oncologic drugs advisory committee recommendations and approval of cancer drugs by the us food and drug administration. JAMA Oncol 2016; 2(6): 744-50.